在临床试验中,通过Mitsunobu和S N Ar反应合成(S)-3-氨基-苯并[ b ] [1,4]恶唑啉-4-酮化合物,用于一流的RIP1激酶抑制剂GSK2982772
摘要:
开发了两种新的合成途径来制备RIP1激酶抑制剂临床候选药物GSK2982772,涉及通过Mitsunobu和S N Ar环化反应制备的关键(S)-3-氨基-苯并[ b ] [1,4]氧杂a-4-酮中间体。与最初的药物化学方法相比,这两种方法都是实用且具有成本效益的,并且也适用于按千克放大以支持正在进行的临床研究。
polyrimetric kinetic study, of the epimerisation of optically pure spirophosphoranes derived from α-aminoalcohols or α-aminoacids, leads to mechanistic conclusions. Evidence from isotopic, solvent and concentration effects and values of the activation parameters are consistent with a regular epimerisation mechanism in these spirophosphoranes involving the intramolecular stereolability of these molecules